Drug Profile

EXS 74539

Alternative Names: '539; EXS-74539; REC-4539

Latest Information Update: 14 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb; Exscientia
Developer Recursion Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Lysine specific demethylase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours
Preclinical Acute myeloid leukaemia

Most Recent Events

08 Apr 2026 Phase-I clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT07517198)
25 Feb 2026 Exscientia plans a phase I/II ENLYGHT trial for Acute myeloid leukaemia in the US in H1 of 2026
07 Jan 2025 US FDA approves IND application for EXS 74539 in olid tumours including small cell lung cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com